JAK inhibitors: a promising direction for treating Rheumatoid Arthritis
<p>Rheumatoid Arthritis (RA) is a chronic auto inflammatory disease that causes incapacitating changes both the musculoskeletal system and the internal organs [1]. Tumor Necrosis Factor inhibitors (TNFi) promised a new revolutionary era in RA approximately 20 years ago. Since then, different T...
Saved in:
Main Author: | Pelechas Eleftherios (Author) |
---|---|
Format: | Book |
Published: |
International Journal of Pharmaceutical Sciences and Developmental Research - Peertechz Publications,
2017-06-09.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Rheumatoid arthritis: Treatment evolution over the years
by: Eleftherios Pelechas, et al.
Published: (2020) -
Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
by: Vishal R. Tandon, et al.
Published: (2022) -
Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis
by: Cutolo M, et al.
Published: (2013) -
JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data
by: Harrington R, et al.
Published: (2020) -
Preclinical Characterization of the Selective JAK1 Inhibitor LW402 for Treatment of Rheumatoid Arthritis
by: Zhang N, et al.
Published: (2021)